The Week in Review: Deals and Collaborations

California's stem cell institute has signed an MOU with China's Ministry of Science and Technology, though details will not be released until next week; ChinaSF, the San Francisco agency in charge of outreach to China businesses, signed a MOU with China Medical City of Taizhou; China Pediatric Pharmaceuticals completed a reverse merger; Starr International agreed to invest $20.5 million in Techpool Bio-Pharma Company; Tongjitang Chinese Medicines announced a 19.3 million share buyback; Merial broke ground on a $70 million expansion of its Nanchang Park manufacturing facility; Servier is collaborating with the Shanghai Institute of Materia Medica on new cancer therapies; China investigators have shown bioluminescence imaging (BLI) can be used to monitor tumors in the eye; Celsion received SFDA approval to include China sites a clinical trial of a new liver cancer therapy; and finally, Biostar Pharma was awarded a China patent for a new TCM treatment for hepatitis B. More details... Stock Symbols: (OTCBB: LHSI) (NYSE: TCM) (NSDQ: CLSN) (OTCBB: BSPM)